LEGN · Legend Biotech Corp
$20.37
+0.10 (+0.49%)
At close · Aug 14
Market Cap
$3.95B
Shares
193.77M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.37
Open$20.17
Day$19.87–20.44
52W close$16.65–37.71
Avg vol 30d2.6M
Short int18.1M · 9.3% float · 6.0d
Short vol39%
Last earningsAug 11, 2026
DataJun 2020–Aug 2026
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
−22%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
18%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+3%
trailing
YTD return
−6%
this year
Relative strength
−11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $26 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +55 funds added
Insider flow
Distributing
Net -$171.1K over 90 days · 100% sells
Short interest
Rising
9.35% of float · ▲ +28.7% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
217 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Gross margin on net product sales
· second quarter
at least 50%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
18%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $26 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +55 funds added
Insider flow
Distributing
Net -$171.1K over 90 days · 100% sells
Short interest
Rising
9.35% of float · ▲ +28.7% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
217 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $17
Now $20 · 18%
Range high $38
vs 200-day avg -15%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LEGN
this stock
Legend Biotech Corp
|
$3.95B | -6.3% | — | — | 9.3% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LEGN | -1.8% | -8.5% | +3.1% | +9.8% | -6.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.2% | -12.9% | -10.6% | +5.9% | -20.2% |
Key facts
CIK
1801198
CUSIP
52490G102
13F (30d)
222 filings
208 filers
Visit website
Investor relations